3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 4
3
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Hepatocellular
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Carcinoma, Renal Cell
7
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Advanced Endometrial Cancer
1
Interventions
Iodine-131
3
Thyrotropin Alfa
2
vandetanib
1
lenvatinib
1
fosbretabulin
1
combretastatin
1
cabozantinib
1
Thyroidectomy
1
Sorafenib
1
Ropivacaine
1
Radiotherapy
1
Paclitaxel
1
Neck Dissection
1
Metformin
1
Epinephrine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Thyroid Neoplasms
×
lenvatinib
×
Clear all
NCT01321554
2023-06-22
SELECT
Eisai Inc.
Phase 3
Completed
392 enrolled
10 charts